A Multi-center、Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this prospective observational study is to learn about the treatment decisions in advanced colorectal cancer treated with oxaliplatin and irinotecan. The main questions:1. learn about the efficacy and safety of immunotherapy or targeted drugs or other chemotherapy for patients treated with oxaliplatin and irinotecan(non-retreatment/rechallenge group,NR group). 2. learn about the efficacy and safety of oxaliplatin or irinotecan for patients treated with oxaliplatin and irinotecan (retreatment/rechallenge group, RT/RC group). 3. compare the efficacy and safety of various treatment regimens for patients treated with oxaliplatin and irinotecan. This study will only collect the clinical data of patients, without any intervention, in the treatment services. All participants will be provided written informed consent as per the Declaration of Helsinki principles.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Phologically confirmed colorectal adenocarcinoma

• Treated by oxaliplatin and irinotecan and discontinued due to progression or intolerable drug toxicity

• ECOG 0-2

• Predicted survival more than 3 months

• Estimated by investigators that the main organ function is enough good to tolerate the next treatment plan.

• Sign informed consent.

• Agree to receive survival follow-up

Locations
Other Locations
China
Sun Yat-sen University Cancer Center
RECRUITING
Guangzhou
Contact Information
Primary
Dongsheng Zhang, MD., phD.
zhangdsh@sysucc.org.cn
86+020-87343795
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 500
Treatments
NR group (Non-retreatment/rechallenge group)
participants who receive immunotherapy or targeted drugs or other chemotherapy beyond treated with oxaliplatin and irinotecan
RT group (Retreatment group)
participants retreated oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed after 3 months of oxaliplatin or irinotecan discontinuation.
RC group (Rechallenge group)
participants rechallenging oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed within 3 months of oxaliplatin or irinotecan discontinuation.
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-sen University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials